The post Strive acquires Semler Scientific in Bitcoin-focused merger appeared on BitcoinEthereumNews.com. Strive, Inc. said on Monday that it will acquire Semler Scientific, Inc. in an all-stock transaction that will significantly expand its corporate Bitcoin holdings. The merger values Semler at a 210% premium, with each of its shares exchanged for 21.05 Strive Class A shares. Alongside the announcement, Strive disclosed the purchase of 5,816 Bitcoin at an average cost of $116,047 each, or roughly $675 million, bringing its total treasury to 5,886 Bitcoin. After closing, the combined company expects to hold more than 10,900 Bitcoin, a figure that would place it among the fastest-growing corporate Bitcoin holders. Strive, which went public in 2022 as the first Bitcoin-focused asset manager, has pursued a strategy of accumulating Bitcoin per share to outperform the asset long-term. By contrast, Semler Scientific entered the market as the second U.S. public firm to adopt Bitcoin as a primary reserve asset, funding purchases with equity and cash flows from its medical diagnostics operations. Semler’s flagship product, QuantaFlo, is an FDA-cleared test for peripheral arterial disease. The merged company plans to explore monetizing or distributing this diagnostics business while expanding into preventative healthcare. The boards of both companies unanimously approved the transaction, which is subject to standard regulatory and shareholder approvals. Strive’s management team will remain in place, while Semler’s executive chairman Eric Semler is expected to join the board. The companies say they intend to pursue a “preferred equity only” model to avoid debt risks common in leveraged Bitcoin strategies. This is a developing story. This article was generated with the assistance of AI and reviewed by editor Jeffrey Albus before publication. Get the news in your inbox. Explore Blockworks newsletters: Source: https://blockworks.co/news/strive-acquires-semlerThe post Strive acquires Semler Scientific in Bitcoin-focused merger appeared on BitcoinEthereumNews.com. Strive, Inc. said on Monday that it will acquire Semler Scientific, Inc. in an all-stock transaction that will significantly expand its corporate Bitcoin holdings. The merger values Semler at a 210% premium, with each of its shares exchanged for 21.05 Strive Class A shares. Alongside the announcement, Strive disclosed the purchase of 5,816 Bitcoin at an average cost of $116,047 each, or roughly $675 million, bringing its total treasury to 5,886 Bitcoin. After closing, the combined company expects to hold more than 10,900 Bitcoin, a figure that would place it among the fastest-growing corporate Bitcoin holders. Strive, which went public in 2022 as the first Bitcoin-focused asset manager, has pursued a strategy of accumulating Bitcoin per share to outperform the asset long-term. By contrast, Semler Scientific entered the market as the second U.S. public firm to adopt Bitcoin as a primary reserve asset, funding purchases with equity and cash flows from its medical diagnostics operations. Semler’s flagship product, QuantaFlo, is an FDA-cleared test for peripheral arterial disease. The merged company plans to explore monetizing or distributing this diagnostics business while expanding into preventative healthcare. The boards of both companies unanimously approved the transaction, which is subject to standard regulatory and shareholder approvals. Strive’s management team will remain in place, while Semler’s executive chairman Eric Semler is expected to join the board. The companies say they intend to pursue a “preferred equity only” model to avoid debt risks common in leveraged Bitcoin strategies. This is a developing story. This article was generated with the assistance of AI and reviewed by editor Jeffrey Albus before publication. Get the news in your inbox. Explore Blockworks newsletters: Source: https://blockworks.co/news/strive-acquires-semler

Strive acquires Semler Scientific in Bitcoin-focused merger

2025/09/23 01:38
Okuma süresi: 2 dk

Strive, Inc. said on Monday that it will acquire Semler Scientific, Inc. in an all-stock transaction that will significantly expand its corporate Bitcoin holdings.

The merger values Semler at a 210% premium, with each of its shares exchanged for 21.05 Strive Class A shares. Alongside the announcement, Strive disclosed the purchase of 5,816 Bitcoin at an average cost of $116,047 each, or roughly $675 million, bringing its total treasury to 5,886 Bitcoin.

After closing, the combined company expects to hold more than 10,900 Bitcoin, a figure that would place it among the fastest-growing corporate Bitcoin holders.

Strive, which went public in 2022 as the first Bitcoin-focused asset manager, has pursued a strategy of accumulating Bitcoin per share to outperform the asset long-term. By contrast, Semler Scientific entered the market as the second U.S. public firm to adopt Bitcoin as a primary reserve asset, funding purchases with equity and cash flows from its medical diagnostics operations.

Semler’s flagship product, QuantaFlo, is an FDA-cleared test for peripheral arterial disease. The merged company plans to explore monetizing or distributing this diagnostics business while expanding into preventative healthcare.

The boards of both companies unanimously approved the transaction, which is subject to standard regulatory and shareholder approvals. Strive’s management team will remain in place, while Semler’s executive chairman Eric Semler is expected to join the board.

The companies say they intend to pursue a “preferred equity only” model to avoid debt risks common in leveraged Bitcoin strategies.

This is a developing story.


This article was generated with the assistance of AI and reviewed by editor Jeffrey Albus before publication.


Get the news in your inbox. Explore Blockworks newsletters:

Source: https://blockworks.co/news/strive-acquires-semler

Piyasa Fırsatı
Union Logosu
Union Fiyatı(U)
$0.000904
$0.000904$0.000904
+2.96%
USD
Union (U) Canlı Fiyat Grafiği
Sorumluluk Reddi: Bu sitede yeniden yayınlanan makaleler, halka açık platformlardan alınmıştır ve yalnızca bilgilendirme amaçlıdır. MEXC'nin görüşlerini yansıtmayabilir. Tüm hakları telif sahiplerine aittir. Herhangi bir içeriğin üçüncü taraf haklarını ihlal ettiğini düşünüyorsanız, kaldırılması için lütfen [email protected] ile iletişime geçin. MEXC, içeriğin doğruluğu, eksiksizliği veya güncelliği konusunda hiçbir garanti vermez ve sağlanan bilgilere dayalı olarak alınan herhangi bir eylemden sorumlu değildir. İçerik, finansal, yasal veya diğer profesyonel tavsiye niteliğinde değildir ve MEXC tarafından bir tavsiye veya onay olarak değerlendirilmemelidir.

Ayrıca Şunları da Beğenebilirsiniz

Cashing In On University Patents Means Giving Up On Our Innovation Future

Cashing In On University Patents Means Giving Up On Our Innovation Future

The post Cashing In On University Patents Means Giving Up On Our Innovation Future appeared on BitcoinEthereumNews.com. “It’s a raid on American innovation that would deliver pennies to the Treasury while kneecapping the very engine of our economic and medical progress,” writes Pipes. Getty Images Washington is addicted to taxing success. Now, Commerce Secretary Howard Lutnick is floating a plan to skim half the patent earnings from inventions developed at universities with federal funding. It’s being sold as a way to shore up programs like Social Security. In reality, it’s a raid on American innovation that would deliver pennies to the Treasury while kneecapping the very engine of our economic and medical progress. Yes, taxpayer dollars support early-stage research. But the real payoff comes later—in the jobs created, cures discovered, and industries launched when universities and private industry turn those discoveries into real products. By comparison, the sums at stake in patent licensing are trivial. Universities collectively earn only about $3.6 billion annually in patent income—less than the federal government spends on Social Security in a single day. Even confiscating half would barely register against a $6 trillion federal budget. And yet the damage from such a policy would be anything but trivial. The true return on taxpayer investment isn’t in licensing checks sent to Washington, but in the downstream economic activity that federally supported research unleashes. Thanks to the bipartisan Bayh-Dole Act of 1980, universities and private industry have powerful incentives to translate early-stage discoveries into real-world products. Before Bayh-Dole, the government hoarded patents from federally funded research, and fewer than 5% were ever licensed. Once universities could own and license their own inventions, innovation exploded. The result has been one of the best returns on investment in government history. Since 1996, university research has added nearly $2 trillion to U.S. industrial output, supported 6.5 million jobs, and launched more than 19,000 startups. Those companies pay…
Paylaş
BitcoinEthereumNews2025/09/18 03:26
Spur Protocol Daily Quiz 21 February 2026: Claim Free Tokens and Boost Your Crypto Wallet

Spur Protocol Daily Quiz 21 February 2026: Claim Free Tokens and Boost Your Crypto Wallet

Spur Protocol Daily Quiz February 21 2026: Today’s Correct Answer and How to Earn Free In-App Tokens The Spur Protocol Daily Quiz for February 21, 2026, is
Paylaş
Hokanews2026/02/21 17:10
Alex Acosta Tells Congress He Has No ‘Remorse’ For Jeffrey Epstein ‘Sweetheart Deal,’ Lawmaker Says

Alex Acosta Tells Congress He Has No ‘Remorse’ For Jeffrey Epstein ‘Sweetheart Deal,’ Lawmaker Says

The post Alex Acosta Tells Congress He Has No ‘Remorse’ For Jeffrey Epstein ‘Sweetheart Deal,’ Lawmaker Says appeared on BitcoinEthereumNews.com. Topline A central figure in the Jeffrey Epstein sexual abuse saga—former prosecutor Alex Acosta, who granted in 2007 the former financier what’s been widely blasted as a “sweetheart deal” for his alleged crimes—has no regrets about the agreement, a Democratic lawmaker told CNN on Friday, as the former Trump official faces questioning from the House Oversight Committee. Alex Acosta, center, arrives for a House Oversight Committee deposition about Jeffrey Epstein on September 19 in Washington D.C. CQ-Roll Call, Inc via Getty Images Key Facts This story is breaking and will be updated. Source: https://www.forbes.com/sites/alisondurkee/2025/09/19/prosecutor-acosta-who-gave-epstein-sweetheart-deal-testifies-he-no-remorse-lawmaker-says/
Paylaş
BitcoinEthereumNews2025/09/20 06:37